Veyonda is a first-in-class activator of the innate immune system. This is the system that scientists increasingly are beginning to see must be activated if a cancer is to have any chance of being permanently eradicated.
Establishing Veyonda as an essential adjunct to radiotherapy in the treatment of prostate cancer and discharging portfolio risk by studying Veyonda in combination with radiotherapy and non-radio therapy treatments.
Read here further details, including links to the ASX announcement and the conference abstract
AddressLevel 4, 828 Pacific Highway Gordon. 2072 NSW AUSTRALIA
PO Box 292, Gordon
2072 NSW AUSTRALIA
50 608 966 123
Join our mailing list to receive the latest information from Noxopharm Limited